Our lead disease-modifying drug is
currently undergoing clinical trials

No one should suffer
from neuropathy

Help us help you by sharing
your experiences and insight

Participate in our short
Patient Survey

  • Unmed Need

Neuropathy affects nearly 1 in 15 Americans. It is one of the largest unmet medical chal lenges existing today, with no FDA-approved treatments outside analgesics.

Peripheral Neuropathies
  • Breakthrough

We are working to treat peripheral neuropathy by reversing and regenerating nerves. Our results validate the discovery of a pathway to augment nerve growth and sensory function.

Our Solution
  • Drive

Who We Are:
+ Key Opinion Leaders
+ Leading Institutional Stakeholders
+ Proven Management Team
+ World Class Advisors

The Team
  • Strategy

We are focused on managing global resources to accelerate the development of treatment for patients with peripheral neuropathy.

Pipeline

Meet June

June is an 85-year-old woman who got neuropathy from the radiation treatment for her breast cancer. She has lost feeling in her feet and experiences numbing in her calves. Like so many others, she now has to use a walker.

Read More Patient Testimonials

Investors

WinSanTor Inc. is a private biotechnology company focused on the discovery and development of treatments for peripheral neuropathies. WinSanTor recently completed Phase 1 trials for its lead drug, WST-057, and will begin recruiting for its Phase 2 trials in Canada to treat patients with diabetic peripheral neuropathy.

INVESTOR INFORMATION
Go to Top